A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Keiko Yamaoka; Shuichi Nagashima; Nobukazu Okada; Nagisa Sawayama; Shinsuke Saito; Manabu Takahashi; Kenta Okada; Kazuhiro Endo; Masaru Koizumi; Hideki Sasanuma; Ken Ebihara; Atsuko Kasajima; Noriyoshi Fukushima; Naohiro Sata; Shun Ishibashi

doi:10.1002/ccr3.4118

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Clin Case Rep. 2021 May 19;9(5):e04118. doi: 10.1002/ccr3.4118. eCollection 2021 May.

Authors

Affiliations

¹ Division of Endocrinology and Metabolism Department of Medicine Jichi Medical University Shimotsuke Japan.
² Department of Surgery Jichi Medical University Shimotsuke Japan.
³ Department of Pathology Tohoku University Graduate School of Medicine Sendai Japan.
⁴ Present address: Department of Pathology Technical University Munich Munich Germany.
⁵ Department of Pathology Jichi Medical University Shimotsuke Japan.

Abstract

Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.

Keywords: hypoglycemia; insulinoma; lanreotide; octreotide; somatostatin analog.

Publication types

Case Reports